Forest Laboratories, Inc. and Phenomix Corporation in $340 Million Diabetes Deal

This post was commissioned on October 24, 2008, and it was categorized as License/Partnership.

Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.

Forest Laboratories and Phenomix Corporation have entered into a definitive collaboration agreement to develop and commercialize dutogliptin (PHX1149) in North America. Dutogliptin is Phenomix’ proprietary orally administered, small molecule dipeptidyl-peptidase-4 (DPP-4) inhibitor currently undergoing Phase 3 clinical development in Type 2 diabetes mellitus.

Terms
——————————-
Codevelopment and Copromotion
Upfront: $75M
Milestones: $340M
Forest will pay Phenomix a royalty on North American revenue
Phenomix retains ex-US, worldwide rights and will pay Forest a royalty on sales in these areas

Forest Laboratories, Inc. and Phenomix Corporation in $340 Million Diabetes Deal
-(Via BioSpace.com Featured News and Stories.)

Theoretically Related Posts

September 19, 2008 -- Maxygen and Astellas Ink Deal for Autoimmune Diseases (1)
December 12, 2008 -- BMS Drops 240M For Codevelopment of 2 Exelixis Cancer Drugs (1)
October 30, 2008 -- EMD Serono Snags US license for Tesamorelin From Theratechnologies (0)
January 9, 2009 -- Alnylam and Cubist to Codevelop Respiratory Syncytial Virus (RSV) Infection Therapy (3)
November 10, 2008 -- BTG Inks $320 Million Preclinical Deal With Onyx (0)
October 23, 2008 -- GlaxoSmithKline and AFFiRiS Ink Alzheimer’s Disease Vaccine Deal (0)
September 10, 2008 -- GSK and Cellzome Announce Alliance over Kinase Technology (0)
May 13, 2008 -- BMS Picks Up KAI-9803 (0)
April 25, 2008 -- Astellas Pharma and CoMentis Sign $760M Alzheimer’s Deal (1)
February 18, 2009 -- Lilly Taps NeuroSearch For Preclinical Discovery Deal (0)

This post was constructed by

Eben Tessari

.

Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis. Agree or disagree with what he's posted? He encourages comments.

If one were so inclined, one could follow him at any of these fine web 2.0 establishments: